US FDA Approves Idorsia’s Once-Daily TRYVIO (Aprocitentan) – The First and Only Endothelin Receptor Antagonist for the Treatment of High Blood Pressure Not Adequately Controlled in Combination with Other Antihypertensives

Idorsia Ltd. announced that the US FDA has approved TRYVIO™ (aprocitentan) for the treatment of hypertension in combination with other antihypertensive drugs, to lower blood pressure in adult patients who are not adequately controlled on other drugs.